<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-14" updated="2020-01-02">
  <drugbank-id primary="true">DB06794</drugbank-id>
  <name>Lodoxamide</name>
  <description>Lodoxamide is a mast-cell stabilizer for topical administration into the eye. Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. These conditions often require treatment with anti-inflammatory medications such as ophthalmic NSAIDs or topical steroids which may cause systemic or toxic effects long-term. Although less effective than topical steroids at decreasing inflammation, mast-cell stabilizers offer another treatment option and exhibit minimal adverse effects. Lodoxamide is marketed under the brand name Alomide by Alcon.</description>
  <cas-number>53882-12-5</cas-number>
  <unii>SPU695OD73</unii>
  <average-mass>311.63</average-mass>
  <monoisotopic-mass>310.9945126</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7097</ref-id>
        <pubmed-id>10890862</pubmed-id>
        <citation>Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L: Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology. 2000 Jul;107(7):1333-7.</citation>
      </article>
      <article>
        <ref-id>A7098</ref-id>
        <pubmed-id>8740338</pubmed-id>
        <citation>Lee S, Allard TR: Lodoxamide in vernal keratoconjunctivitis. Ann Pharmacother. 1996 May;30(5):535-7.</citation>
      </article>
      <article>
        <ref-id>A7099</ref-id>
        <pubmed-id>21465936</pubmed-id>
        <citation>Das D, Khan M, Gul A, Alam R: Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. J Pak Med Assoc. 2011 Mar;61(3):239-41.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.</indication>
  <pharmacodynamics>Lodoxamide is a mast cell stabilizer that inhibits the in vivo Type 1 immediate hypersensitivity reaction. Lodoxamide therapy inhibits the increases in cutaneous vascular permeability that are associated with reagin or IgE and antigen-mediated reactions.</pharmacodynamics>
  <mechanism-of-action>Although lodoxamide's precise mechanism of action is unknown, it is postulated that it prevents calcium influx into mast cells upon antigen stimulation and therefore stabilizes the membrane. By stabilizing the mast cell membrane from degranulation, lodoxamide consequently inhibits the release of intracellular histamine and other chemoattractant factors that primarily cause ocular symptoms. Lodoxamide's mechanism of action may be similar to cromolyn sodium, as both exhibit cross-tachyphylaxis. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>In a study of twelve healthy adult volunteers, topical administration of lodoxamide tromethamine ophthalmic solution 0.1%, one drop in each eye four times per day for ten days, did not result in any measurable lodoxamide plasma levels at a detection limit of 2.5 ng/mL. </absorption>
  <half-life>Elimination half-life was 8.5 hours in urine.</half-life>
  <protein-binding/>
  <route-of-elimination>Urinary excretion is the major route of elimination.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.</description>
    <direct-parent>Alpha amino acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>Anilides</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Benzonitriles</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Chlorobenzenes</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-arylamides</alternative-parent>
    <alternative-parent>Nitriles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Anilide</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzonitrile</substituent>
    <substituent>Carbonitrile</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-arylamide</substituent>
    <substituent>Nitrile</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001178</drugbank-id>
      <name>Lodoxamide tromethamine</name>
      <unii>50LV9A548L</unii>
      <cas-number>63610-09-3</cas-number>
      <inchikey>JJOFNSLZHKIJEV-UHFFFAOYSA-N</inchikey>
      <average-mass>553.91</average-mass>
      <monoisotopic-mass>553.1422991</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="spanish" coder="">Lodoxamida</synonym>
    <synonym language="english" coder="inn">Lodoxamide</synonym>
    <synonym language="english" coder="">N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alomide</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00893560</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.1 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alomide</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-0345</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA020191</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Alomide</name>
      <ingredients>Lodoxamide</ingredients>
    </mixture>
    <mixture>
      <name>Alomide</name>
      <ingredients>Lodoxamide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Aldehydic</category>
      <mesh-id>D000145</mesh-id>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Amino Acids</category>
      <mesh-id>D000596</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Allergic Agents</category>
      <mesh-id>D018926</mesh-id>
    </category>
    <category>
      <category>Antioxidants</category>
      <mesh-id>D000975</mesh-id>
    </category>
    <category>
      <category>Decongestants and Antiallergics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Decreased Histamine Release</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Glyoxylates</category>
      <mesh-id>D006038</mesh-id>
    </category>
    <category>
      <category>Histamine Agents</category>
      <mesh-id>D018494</mesh-id>
    </category>
    <category>
      <category>Mast Cell Stabilizers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Propylene Glycols</category>
      <mesh-id>D011409</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>0.1 %</strength>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength>1 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01GX05">
      <level code="S01GX">Other antiallergics</level>
      <level code="S01G">DECONGESTANTS AND ANTIALLERGICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:02.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06794.pdf?1453495254</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.72</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.61e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>{[3-(carboxyformamido)-2-chloro-5-cyanophenyl]carbamoyl}formic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>lodoxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>311.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>310.9945126</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11H6ClN3O6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RVGLGHVJXCETIO-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>156.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>69.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>26.52</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-6.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>0.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11177</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>135333</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>44564</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310264890</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04762</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>40543</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lodoxamide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201266</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/alomide-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/pro/alomide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>